References
- Lebwohl M. Psoriasis. Lancet. 2003;361:1197–1204.
- American Academy of Dermatology. What is psoriasis? 2011. 8-6-2007.
- Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol. 2008;59:772–780.
- Bonifati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol. 1999;38:241–251.
- Mussi A, Bonifati C, Carducci M, D'Agosto G, Pimpinelli F, D'Urso D, Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents. 1997;11:115–118.
- Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol. 1994;96:146–151.
- Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009;68:702–709.
- Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264–2272.
- Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52:1227–1236.
- Thayer S, Watson C, Song R, Globe DR, Harrison DJ. Etanercept treatment patterns in managed-care patients with psoriasis or psoriatic arthritis. J Med Econ. 2010;13:228–235.
- Public Law 104-191 1C. Health Insurance Portability and Accountability Act of 1996. 2009. 6-17-2011.
- Richards HL, Ray DW, Kirby B, Mason D, Plant D, Main CJ, Response of the hypothalamic-pituitary-adrenal axis to psychological stress in patients with psoriasis. Br J Dermatol. 2005;153:1114–1120.